Brief: Iovance Biotherapeutics Q3 Net Income USD -83.541 Million
07/11/2024 21:01
Nov 07 (Reuters) - Iovance Biotherapeutics Q3 operating income USD -89.066 million. * Q3 pretax profit USD -85.061 million
Recent news on Iovance Biotherapeutics
See all newsBrief: Iovance Biotherapeutics Reports Inducement Grants
US RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Brief: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer
Iovance hits two-year high after raising annual revenue forecast
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies